Europe PMC
open access
CC BY 4.0
An in silico VAR2CSA-based multi-epitope vaccine candidate (PM-MEV-k1) shows favourable Structural and Immune Simulation parameters for protection against placental malaria
Abstract Background Placental malaria remains a major cause of maternal anaemia, low birth weight, and infant mortality across sub-Saharan Africa, yet no licensed vaccine currently exists. VAR2CSA mediates parasite sequestration in the placenta, but candidates PRIMVAC and PAMVA
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides#67659
- Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted#411249
- MiMBa Pregnancy Registry#1139177
- Genetic diversity in the Plasmodium falciparum next-generation blood stage vaccine candidate antigen PfCyRPA in Senegal#300957
- Prevalence and Impact of COVID-19 on Maternal and Infant Health in African Populations#1172715
Record · ID 1175120
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive